Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...